Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients
| Autor: | Fortunato Morabito, Ernesto Vigna, Rosellina Morelli, Carla Mazzone, A. De Vivo, Eugenio Lucia, Massimo Gentile, Anna Grazia Recchia, Nicola Vianelli |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Transplantation
biology business.industry Zoonosis Human immunodeficiency virus (HIV) Leishmaniasis medicine.disease Leishmania biology.organism_classification medicine.disease_cause Virology Infectious Diseases Visceral leishmaniasis Pharmacotherapy Amphotericin B Immunology medicine Liposomal amphotericin business medicine.drug |
| Zdroj: | Transplant Infectious Disease. 12:428-431 |
| ISSN: | 1398-2273 |
| Popis: | E. Vigna, A. De Vivo, M. Gentile, R. Morelli, E. Lucia, C. Mazzone, A.G. Recchia, N. Vianelli, F. Morabito. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients. Transpl Infect Dis 2010: 12: 428–431. All rights reserved. Abstract: Leishmaniasis is a zoonosis caused by a protozoan of the Leishmania genus. First-line treatment for all forms is currently represented by the use of antimony derivatives, although toxic effects and the number of resistant strains in both immunocompromised and immunocompetent patients is increasing. Liposomal amphotericin B (L-AMB) is less toxic, more effective, and better tolerated, especially in human immunodeficiency virus-negative immunocompromised patients. We present 2 cases of transplanted patients affected by visceral leishmaniasis treated successfully with L-AMB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|